The incretins: a link between nutrients and well-being
暂无分享,去创建一个
[1] P. Jehle,et al. Effects of glucagon-like peptide-1 (GLP-1) in RINm5F insulinoma cells. Stimulation of insulin secretion, insulin content, and insulin receptor binding. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[2] B. Ahrén. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.
[3] M. Mattson,et al. Learning from the gut , 2003, Nature Medicine.
[4] W. Banks,et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection , 2003, Nature Medicine.
[5] D. Drucker,et al. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. , 2001, Diabetes.
[6] R. Burcelin,et al. Evidence that extrapancreatic GLUT2-dependent glucose sensors control glucagon secretion. , 2001, Diabetes.
[7] R. Burcelin,et al. Glucose sensing by the hepatoportal sensor is GLUT2-dependent: in vivo analysis in GLUT2-null mice. , 2000, Diabetes.
[8] Xia Li,et al. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.
[9] R. Burcelin,et al. Portal glucose infusion in the mouse induces hypoglycemia: evidence that the hepatoportal glucose sensor stimulates glucose utilization. , 2000, Diabetes.
[10] J. Holst,et al. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. , 2000, European journal of pharmacology.
[11] M. A. Gülpınar,et al. Glucagon-like peptide (GLP-1) is involved in the central modulation of fecal output in rats. , 2000, American journal of physiology. Gastrointestinal and liver physiology.
[12] E. Blázquez,et al. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. , 2000, Metabolism: clinical and experimental.
[13] J. Holst,et al. Short-term treatment with GLP-1 increases pulsatile insulin secretion in Type II diabetes with no effect on orderliness , 2000, Diabetologia.
[14] S. Bloom,et al. Effect of leptin on hypothalamic GLP-1 peptide and brain-stem pre-proglucagon mRNA. , 2000, Biochemical and biophysical research communications.
[15] J. Miyazaki,et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[16] G. Pacini,et al. Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice. , 1999, American journal of physiology. Endocrinology and metabolism.
[17] J. Habener,et al. The glucagon-like peptides. , 1999, Endocrine reviews.
[18] A. Buchan,et al. Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine , 1999, Cell and Tissue Research.
[19] G. V. Dijk,et al. Glucagon-like peptide-1 (7–36) amide: a central regulator of satiety and interoceptive stress , 1999, Neuropeptides.
[20] S. Germain,et al. Encapsulated, Genetically Engineered Cells, Secreting Glucagon‐like Peptide‐1 for the Treatment of Non‐insulin‐dependent Diabetes Mellitus , 1999, Annals of the New York Academy of Sciences.
[21] M. Wolfe,et al. Effect of GIP and GLP-1 antagonists on insulin release in the rat. , 1999, American journal of physiology. Endocrinology and metabolism.
[22] M. Nauck. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective , 1998, Acta Diabetologica.
[23] Christine M. Williams,et al. Insulin, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide and insulin-like growth factor I as putative mediators of the hypolipidemic effect of oligofructose in rats. , 1998, The Journal of nutrition.
[24] S. Woods,et al. Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats , 1998, Brain Research.
[25] A. R. Durrant,et al. Circulating leptin does not appear to provide a signal for triggering the initiation of puberty in the male rhesus monkey (Macaca mulatta). , 1997, Endocrinology.
[26] B. Yeğen,et al. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. , 1997, American journal of physiology. Gastrointestinal and liver physiology.
[27] R. Bergman,et al. Novel Glucosensor for Hypoglycemic Detection Localized to the Portal Vein , 1997, Diabetes.
[28] J. Holst,et al. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. , 1997, Gut.
[29] K. Jungermann,et al. Sensing by intrahepatic muscarinic nerves of a portal‐arterial glucose concentration gradient as a signal for insulin‐dependent glucose uptake in the perfused rat liver , 1997, FEBS letters.
[30] M. Furuse,et al. Intracerebroventricular injection of mammalian and chicken glucagon-like peptide-1 inhibits food intake of the neonatal chick , 1997, Brain Research.
[31] B. Göke,et al. [The intestinal hormone glucagon-like peptide 1 (GLP-1): from experiment to the clinic]. , 1997, Zeitschrift fur Gastroenterologie.
[32] G. Ramadori,et al. Release of glucagon-like peptide-1 (GLP-1) by carbohydrates in the perfused rat ileum , 1997, Acta Diabetologica.
[33] J. Holst,et al. Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. , 1997, The Journal of clinical endocrinology and metabolism.
[34] J. Holst,et al. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. , 1997, The Journal of clinical endocrinology and metabolism.
[35] A. Joyner,et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene , 1996, Nature Medicine.
[36] A. Niijima,et al. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. , 1996, The American journal of physiology.
[37] M. Byrne,et al. Human Studies with Glucagon‐like‐peptide‐1: Potential of the Gut Hormone for Clinical Use , 1996, Diabetic medicine : a journal of the British Diabetic Association.
[38] J. Holst,et al. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. , 1996, European journal of endocrinology.
[39] M. Nauck. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes. , 1996, Diabetic medicine : a journal of the British Diabetic Association.
[40] J. Holst. GLP‐1 in NIDDM , 1996, Diabetic medicine : a journal of the British Diabetic Association.
[41] M. McBurney,et al. Dietary fiber modulates intestinal proglucagon messenger ribonucleic acid and postprandial secretion of glucagon-like peptide-1 and insulin in rats. , 1996, Endocrinology.
[42] L. Rossetti,et al. Neural and pancreatic influences on net hepatic glucose uptake and glycogen synthesis. , 1996, The American journal of physiology.
[43] J. Holst,et al. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. , 1996, Scandinavian journal of gastroenterology.
[44] P. Brubaker,et al. Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut. , 1996, Endocrinology.
[45] J. Holst,et al. Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients , 1996, Diabetes Care.
[46] A. Niijima. Afferent impulse discharges from glucoreceptors in the liver of the guinea pig. , 1996, Nutrition.
[47] M. Moore,et al. The nerves, the liver, and the route of feeding: an integrated response to nutrient delivery. , 1996, Nutrition.
[48] B. Thorens,et al. Expression of the Glucagon‐Like Peptide‐1 Receptor Gene in Rat Brain , 1996, Journal of neurochemistry.
[49] J. Holst,et al. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections. , 1996, Zeitschrift fur Gastroenterologie.
[50] W. Zawalich,et al. Glucagon-like peptide-1 stimulates insulin secretion but not phosphoinositide hydrolysis from islets desensitized by prior exposure to high glucose or the muscarinic agonist carbachol. , 1996, Metabolism: clinical and experimental.
[51] D. Smith,et al. A role for glucagon-like peptide-1 in the central regulation of feeding , 1996, Nature.
[52] P. Brubaker,et al. Stereospecific effects of fatty acids on proglucagon-derived peptide secretion in fetal rat intestinal cultures. , 1995, Endocrinology.
[53] D. Steiner,et al. Differential Processing of Proglucagon by the Subtilisin-like Prohormone Convertases PC2 and PC3 to Generate either Glucagon or Glucagon-like Peptide (*) , 1995, The Journal of Biological Chemistry.
[54] P. J. Larsen,et al. Distribution of GLP‐1 Binding Sites in the Rat Brain: Evidence that Exendin‐4 is a Ligand of Brain GLP‐1 Binding Sites , 1995, The European journal of neuroscience.
[55] B. Göke,et al. Molecular cloning, functional expression, and signal transduction of the GIP‐receptor cloned from a human insulinoma , 1995, FEBS letters.
[56] B. Göke,et al. Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. , 1995, The Journal of endocrinology.
[57] D. Hargrove,et al. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. , 1995, Metabolism: clinical and experimental.
[58] J. Holst,et al. Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects , 1995, Diabetes.
[59] J. Habener,et al. Activation of a cAMP-regulated Ca-Signaling Pathway in Pancreatic -Cells by the Insulinotropic Hormone Glucagon-like Peptide-1 (*) , 1995, The Journal of Biological Chemistry.
[60] H. Stunnenberg,et al. Low Affinity Binding of Interleukin-1 and Intracellular Signaling via NF-B Identify Fit-1 as a Distant Member of the Interleukin-1 Receptor Family (*) , 1995, The Journal of Biological Chemistry.
[61] V. Marks,et al. GIP and GLP-1(7-36)amide secretion in response to intraduodenal infusions of nutrients in pigs. , 1995, Comparative biochemistry and physiology. Part C, Pharmacology, toxicology & endocrinology.
[62] J. Cuber,et al. Luminal glucagon-like peptide-1(7-36) amide-releasing factors in the isolated vascularly perfused rat colon. , 1995, The Journal of endocrinology.
[63] J. Holst,et al. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7–36 amide] in the fasting state in healthy subjects , 1995, Acta Diabetologica.
[64] J. Holst,et al. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.
[65] S. Mojsov,et al. Tissue‐specific expression of the human receptor for glucagon‐like peptide‐I: brain, heart and pancreatic forms have the same deduced amino acid sequences , 1995, FEBS letters.
[66] B. Göke,et al. Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin (9–39) Amide , 1995, Diabetes.
[67] J. Holst,et al. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. , 1994, Gastroenterology.
[68] B. Göke,et al. Signal transduction of the GLP‐1‐receptor cloned from a human insulinoma , 1994, FEBS letters.
[69] T. Bamba,et al. Enteroglucagon , 1994, Digestive Diseases and Sciences.
[70] A. Hattersley,et al. Non-linkage of the glucagon-like peptide 1 receptor gene with maturity onset diabetes of the young , 1994, Diabetologia.
[71] M. Permutt,et al. Human Glucagon-Like Peptide-1 Receptor Gene in NIDDM: Identification and Use of Simple Sequence Repeat Polymorphisms in Genetic Analysis , 1994, Diabetes.
[72] D. Drucker,et al. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. , 1994, Endocrinology.
[73] B. Thorens,et al. Signal transduction by the cloned glucagon-like peptide-1 receptor: comparison with signaling by the endogenous receptors of beta cell lines. , 1994, Molecular pharmacology.
[74] D. Steiner,et al. Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[75] J. Holst,et al. Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.
[76] Shaoping Deng,et al. Cloning and Functional Expression of the Human Islet GLP-1 Receptor: Demonstration That Exendin-4 Is an Agonist and Exendin-(9–39) an Antagonist of the Receptor , 1993, Diabetes.
[77] B. Ahrén,et al. Effects of glucagon like-1(7–36)amide on the ctoplasmic Ca2+-concentration in rat islet cells , 1993, Molecular and Cellular Endocrinology.
[78] A. Cherrington,et al. Counterregulation During Hypoglycemia Is Directed by Widespread Brain Regions , 1993, Diabetes.
[79] G. Waeber,et al. Glucagon-Like Peptide-I and the Control of Insulin Secretion in the Normal State and in NIDDM , 1993, Diabetes.
[80] J. Holst,et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients , 1993, Diabetologia.
[81] W. Creutzfeldt,et al. Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells. , 1993, Journal of molecular endocrinology.
[82] H. Rasmussen,et al. Influence of glucagon-like peptide-1 on β cell responsiveness , 1993, Regulatory Peptides.
[83] M. Nauck,et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. , 1993, The Journal of clinical endocrinology and metabolism.
[84] H. Ochi,et al. Possible role of the adrenergic mechanism in gastric inhibitory polypeptide- and glucagon-like peptide-1 (7-36) amide-induced insulin release in the rat. , 1993, Metabolism: clinical and experimental.
[85] J. Habener,et al. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37) , 1993, Nature.
[86] M. Igarashi,et al. Hypersecretion of Truncated Glucagon‐like Peptide‐1 and Gastric Inhibitory Polypeptide in Obese Patients , 1993 .
[87] B. Göke,et al. Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1(7–36)amide on the rat pancreas , 1992, Regulatory Peptides.
[88] M. Igarashi,et al. Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients , 1992, Regulatory Peptides.
[89] M. Igarashi,et al. Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion. , 1992, Diabetes research and clinical practice.
[90] E. Blázquez,et al. Autoradiographic localization of receptors for glucagon-like peptide-1(7–36) amide in rat brain , 1992, Neuropeptides.
[91] D. Nathan,et al. Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects , 1992, Diabetes Care.
[92] A. Cherrington,et al. Magnitude of Negative Arterial-Portal Glucose Gradient Alters Net Hepatic Glucose Balance in Conscious Dogs , 1991, Diabetes.
[93] P. Brubaker. Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. , 1991, Endocrinology.
[94] B. Ahrén,et al. GLP-1(7-36) amide stimulates insulin secretion in rat islets: studies on the mode of action. , 1991, Diabetes research.
[95] B. Göke,et al. Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas. , 1991, Biochimica et biophysica acta.
[96] 小松 良哉. Glucagonostatic and Insulinotropic Action of Glucagonlike Peptide 1-(7-36)-Amide , 1990 .
[97] D. Drucker. Glucagon and the Glucagon‐like Peptides , 1990, Pancreas.
[98] B. Göke,et al. Interaction of glucagon-like peptide-1 (7-36)amide and cholecystokinin-8 in the endocrine and exocrine rat pancreas. , 1990, Pancreas.
[99] S. Bloom,et al. Characterization of glucagon-like peptide-1-(7–36)amide in the hypothalamus , 1989, Brain Research.
[100] B. Göke,et al. Signal transmission after GLP-1(7-36)amide binding in RINm5F cells. , 1989, The American journal of physiology.
[101] M. Namba,et al. Glucagonostatic and Insulinotropic Action of Glucagonlike Peptide I-(7–36)-Amide , 1989, Diabetes.
[102] K. Shima,et al. Identification of Glucagon-Like Peptide-1(7–36) Amide in Rat Brain , 1989, Annals of clinical biochemistry.
[103] A. Cherrington,et al. Role of Brain in Counterregulation of Insulin-Induced Hypoglycemia in Dogs , 1989, Diabetes.
[104] S. Kanse,et al. Identification and characterization of glucagon‐like peptide‐1 7–36 amide‐binding sites in the rat brain and lung , 1988, FEBS letters.
[105] J. Holst,et al. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. , 1988, Endocrinology.
[106] K. Shima,et al. Effect of glucagon-like peptide-1 on insulin secretion , 1988, Regulatory Peptides.
[107] S. Bloom,et al. GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.
[108] J. Holst,et al. Pancreatic and intestinal processing of proglucagon in man , 1987, Diabetologia.
[109] Suzuki,et al. Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[110] K. Shima,et al. Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. , 1987, Endocrinology.
[111] G. Weir,et al. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. , 1987, The Journal of clinical investigation.
[112] J. Holst,et al. Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut , 1987, FEBS letters.
[113] K. Jungermann,et al. A portal‐arterial glucose concentration gradient as a signal for an insulin‐dependent net glucose uptake in perfused rat liver , 1986, FEBS letters.
[114] A. Niijima. Blood glucose levels modulate efferent activity in the vagal supply to the rat liver. , 1985, The Journal of physiology.
[115] L. Thim,et al. The isolation and sequencing of human gastric inhibitory peptide (GIP) , 1984, FEBS letters.
[116] Y. Oomura,et al. Convergence of hepatoportal glucose-sensitive afferent signals to glucose-sensitive units within the nucleus of the solitary tract , 1984, Neuroscience Letters.
[117] W. Creutzfeldt,et al. Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption , 1983, Diabetologia.
[118] Y. Oomura,et al. Functional correlations between lateral hypothalamic glucose-sensitive neurons and hepatic portal glucose-sensitive units in rat , 1983, Brain Research.
[119] H. Berthoud,et al. Evidence for a role of the gastric, coeliac and hepatic branches in vagally stimulated insulin secretion in the rat. , 1983, Journal of the autonomic nervous system.
[120] W. Creutzfeldt,et al. Influence of gastric inhibitory polypeptide antiserum on glucose-induced insulin secretion in rats. , 1982, Endocrinology.
[121] P. Cryer. Glucose Counterregulation in Man , 1981, Diabetes.
[122] Y. Kasuya,et al. Effects of cocaine on Ca-mobility in microsomal fraction from rat vas deferens. , 1981, Japanese journal of pharmacology.
[123] R. Rizza,et al. Hormonal mechanisms in acute glucose counterregulation: the relative roles of glucagon, epinephrine, norepinephrine, growth hormone, and cortisol. , 1980, Metabolism: clinical and experimental.
[124] R. Rizza,et al. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. , 1979, The Journal of clinical investigation.
[125] W. Creutzfeldt,et al. The incretin concept today , 1979, Diabetologia.
[126] J. Polak,et al. Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) im man , 1978, Histochemistry.
[127] J. Holst. Extraction, gel filtration pattern, and receptor binding of porcine gastrointestinal glucagon-like immunoreactivity , 1977, Diabetologia.
[128] M. Sugimori,et al. Glucose Inhibition of the Glucose-sensitive Neurone in the Rat Lateral Hypothalamus , 1974, Nature.
[129] M. Schmitt. Influences of hepatic portal receptors on hypothalamic feeding and satiety centers. , 1973, The American journal of physiology.
[130] J. Brown. A gastric inhibitory polypeptide. I. The amino acid composition and the tryptic peptides. , 1971, Canadian journal of biochemistry.
[131] M. Gerry. Effects of Centrifugal Distortion and Nuclear Quadrupole Coupling in the Microwave Spectrum of Vinyl Chloride , 1971 .
[132] T. Ono,et al. Glucose and Osmosensitive Neurones of the Rat Hypothalamus , 1969, Nature.
[133] D. Kipnis,et al. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. , 1967, The Journal of clinical investigation.
[134] C. Best. The internal secretion of the pancreas. , 1922, Canadian Medical Association journal.
[135] W M Bayliss,et al. The mechanism of pancreatic secretion , 1902, The Journal of physiology.
[136] Gertjan,et al. University of Groningen Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats , 2002 .
[137] R. Bergman,et al. Portal vein afferents are critical for the sympathoadrenal response to hypoglycemia. , 2000, Diabetes.
[138] N. Delzenne,et al. Oligofructose modulates lipid metabolism alterations induced by a fat‐rich diet in rats , 1998, Journal of applied toxicology : JAT.
[139] J. Holst,et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. , 1996, The Journal of clinical endocrinology and metabolism.
[140] B. Göke,et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. , 1996, The Journal of clinical investigation.
[141] T. Rink,et al. Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. , 1996, Metabolism: clinical and experimental.
[142] A. Cherrington,et al. Comparison of the time courses of insulin and the portal signal on hepatic glucose and glycogen metabolism in the conscious dog. , 1996, The Journal of clinical investigation.
[143] D. Smith,et al. Glucagon-like peptide-1 is a physiological incretin in rat. , 1995, The Journal of clinical investigation.
[144] B. Göke,et al. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. , 1995, Digestion.
[145] J. Holst,et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.
[146] H. Rasmussen,et al. Influence of glucagon-like peptide-1 on beta cell responsiveness. , 1993, Regulatory peptides.
[147] B. Ahrén,et al. Effects of glucagon like peptide-1(7-36) amide on the cytoplasmic Ca(2+)-concentration in rat islet cells. , 1993, Molecular and Cellular Endocrinology.
[148] W. Creutzfeldt. Entero-insular axis and diabetes mellitus. , 1992, Hormone and metabolic research. Supplement series.
[149] M. Eggstein,et al. Influence of breakfasts with different nutrient contents on glucose, C peptide, insulin, glucagon, triglycerides, and GIP in non-insulin-dependent diabetics. , 1991, The American journal of clinical nutrition.
[150] Graeme I. Bell,et al. Exon duplication and divergence in the human preproglucagon gene , 1983, Nature.
[151] Y. Oomura,et al. Chemosensitive neuron in the hypothalamus related to food intake behavior. , 1981, Japanese journal of pharmacology.
[152] J. Brown,et al. A multiparameter study on the action of preparations containing cholecystokinin-pancreozymin. , 1970, Scandinavian journal of gastroenterology.
[153] Brown Jc,et al. A multiparameter study on the action of preparations containing cholecystokinin-pancreozymin. , 1970 .
[154] E. S. Edie,et al. On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane. , 1906, The Biochemical journal.
[155] P. Brubaker,et al. Printed in U.S.A. Copyright © 1999 by The Endocrine Society Role of the Vagus Nerve in Mediating Proximal Nutrient- Induced Glucagon-Like Peptide-1 Secretion* , 2022 .